On Monday, Hot Air posted an article about some of the recent developments in dealing with cancer.
The article quotes a New York Times article:
A drug nearing regulatory approval, daraxonrasib, is the first to substantially extend the lives of patients with pancreatic cancer. It works by targeting a cellular protein that fuels not just nearly all pancreatic tumors, but also many lung and colon cancers. Those three are the leading causes of cancer deaths.
Now, some scientists predict that the approach could wind up being the most significant advance in cancer treatment in 15 years, since the arrival of immunotherapy…
The drug that opened the floodgates, daraxonrasib, has been fast-tracked for review by the Food and Drug Administration and could win approval later this year. Until then, the agency has signed off on a plan by Revolution Medicines, the small Silicon Valley company developing the drug, to offer early access to some patients.
The pills, three taken daily, are not a cure — eventually, daraxonrasib stops working. Many patients do not respond. And it has side effects that can be harsh, including rash, diarrhea, fatigue, nausea and raw, split fingertips.
Until now, however, patients with pancreatic cancer have typically been offered grueling chemotherapy that does little to extend their lives.
The article also mentions positive developments in breast cancer and prostate cancer research.
The article concludes:
All of these developments are good news for future patients diagnosed with these cancers and could lead to additional breakthroughs as other companies race to find similar drugs they can bring to market. None of this happens overnight of course but with advances in AI we can expect it to happen much more frequently in the coming years. In ten years time, the cumulative change in treatments and survival rates could be pretty dramatic compared to where we are now.
This is really good news!
